Paluratide NEW
| Price | $3280 | $8930 |
| Package | 5mg | 50mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-20 |
Product Details
| Product Name: Paluratide | CAS No.: 2676177-63-0 |
| Purity: 98.70% | Supply Ability: 10g |
| Release date: 2026/04/20 |
Product Introduction
Bioactivity
| Name | Paluratide |
| Description | Paluratide (LUNA18) is a reversible cyclic peptide KRAS inhibitor with the advantages of oral availability and cell permeability for the treatment of kras-mutant cancers, which inhibits cancer cell proliferation by phosphorylating ERK and AKT, and also inhibits the interaction of RAS with guanine nucleotide exchange factors (GEFs). |
| In vitro | Paluratide is a high-affinity cyclic peptide KRAS inhibitor that blocks KRAS/SOS1 interaction (IC?? ≈ 0.5?nM). Paluratide inhibits proliferation in various KRAS-mutant cells (IC?? = 0.17-2.9?nM) and reduces GTP-KRAS, pERK1/2, and pAKT levels significantly at 100?nM[1]. |
| In vivo | Paluratide shows 21% oral bioavailability in mice and, at 10?mg/kg daily, significantly suppresses tumor growth in KRAS-G12V xenograft models while reducing KRAS pathway activity, with no notable toxicity observed [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (2.3 mM), Sonication is recommended. DMSO : 80 mg/mL (55.65 mM), Sonication is recommended. |
| Inhibitors Related | Aceglutamide | Urea | Gum arabic | RMC-9805 | Hyaluronic acid | Lactose | Ethyl linoleate | Sotorasib | Methyl eugenol | Gluconate Calcium | Daraxonrasib | 2,3-Butanediol |
| Related Compound Libraries | PI3K-AKT-mTOR Compound Library | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
-
CAS:1565759-96-7
-
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY